Drug Combination Details
| General Information of the Combination (ID: C09366) | |||||
|---|---|---|---|---|---|
| Name | Sulforaphane NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of SFN and gemcitabine potentiates the efficacy of gemcitabine and minimize the toxicity to normal cells. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CD44 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PROM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SHH | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SMO | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | ||
| PC9 GT | Non-small cell lung cancer | Homo sapiens | ||||
| Experimental
Result(s) |
SFN inhibits the proliferation of gefitinib-tolerant lung cancer cells via modulation of the SHH signaling pathway. | |||||
